secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-08-06T20:09:05+00:00
Accession:  0001937653-26-000046
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q2 net loss $45M; PDUFA for zanidatamab Aug 25; Theravance acquisition on track
--------------------------------------------------------------------------------

- Net loss of $45.0M in Q2 2026 vs net income of $2.3M in Q2 2025; revenue fell to $4.6M from $48.7M.
- Cash and marketable securities $322.5M as of June 30, 2026; repurchased $49.4M of shares under new $125M program.
- PDUFA target date Aug 25, 2026 for zanidatamab in 1L HER2+ GEA; potential $250M U.S. approval milestone.
- Acquisition of Theravance Biopharma expected to close 2H 2026, adding YUPELRI profit share and ~$60M annualized cash flow.
- R&D expenses down 20% YoY to $27.4M; G&A up to $19.3M on higher stock comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/0001937653-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/zyme-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001937653-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer